Bristol Total Operating Expenses vs Other Operating Expenses Analysis
BMY Stock | USD 44.11 0.44 0.99% |
Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Total Operating Expenses and its Other Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Total Operating Expenses vs Other Operating Expenses
Total Operating Expenses vs Other Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Total Operating Expenses account and Other Operating Expenses. At this time, the significance of the direction appears to have totally related.
The correlation between Bristol Myers' Total Operating Expenses and Other Operating Expenses is 1.0. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Total Operating Expenses and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Bristol Myers Squibb are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Total Operating Expenses i.e., Bristol Myers' Total Operating Expenses and Other Operating Expenses go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bristol Myers Squibb. It is also known as Bristol Myers overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Bristol Myers' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 36.4B | 36.0B | 34.3B | 36.0B | Total Revenue | 46.4B | 46.2B | 45.0B | 47.3B |
Bristol Myers fundamental ratios Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Short Long Term Debt Total | 47.5B | 51.7B | 45.6B | 40.7B | 41.5B | 43.5B | |
Other Current Liab | 7.9B | 10.2B | 10.1B | 13.1B | 11.5B | 12.1B | |
Total Current Liabilities | 18.3B | 19.1B | 21.9B | 21.9B | 22.3B | 23.4B | |
Total Stockholder Equity | 51.6B | 37.8B | 35.9B | 31.1B | 29.4B | 15.0B | |
Property Plant And Equipment Net | 6.3B | 6.7B | 7.0B | 7.5B | 8.0B | 5.2B | |
Net Debt | 35.2B | 37.1B | 31.6B | 31.6B | 30B | 31.5B | |
Retained Earnings | 34.5B | 21.3B | 23.8B | 25.5B | 28.8B | 22.0B | |
Cash | 12.3B | 14.5B | 14.0B | 9.1B | 11.5B | 12.0B | |
Non Current Assets Total | 100.6B | 88.3B | 76.1B | 69.5B | 63.4B | 66.6B | |
Non Currrent Assets Other | 6.6B | 2.1B | 1.7B | 1.0B | 1.9B | 2.0B | |
Cash And Short Term Investments | 12.3B | 14.5B | 14.0B | 9.1B | 12.3B | 12.9B | |
Net Receivables | 7.7B | 8.5B | 12.5B | 13.9B | 15.3B | 16.0B | |
Good Will | 22.5B | 20.5B | 20.5B | 21.1B | 21.2B | 22.2B | |
Common Stock Shares Outstanding | 1.7B | 2.3B | 2.2B | 2.1B | 2.1B | 1.6B | |
Liabilities And Stockholders Equity | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Non Current Liabilities Total | 59.9B | 61.5B | 51.4B | 43.8B | 43.4B | 45.6B | |
Inventory | 4.3B | 2.1B | 2.1B | 2.3B | 2.7B | 1.9B | |
Other Current Assets | 2.0B | 1.4B | 1.3B | 1.6B | 1.5B | 1.8B | |
Other Stockholder Equity | 18.4B | 18.1B | 13.1B | 6.5B | 1.9B | 2.0B | |
Total Liab | 78.2B | 80.6B | 73.3B | 65.7B | 65.7B | 69.0B | |
Property Plant And Equipment Gross | 6.3B | 5.9B | 11.0B | 11.6B | 12.8B | 13.5B | |
Total Current Assets | 29.4B | 30.2B | 33.3B | 27.3B | 31.8B | 33.4B | |
Accumulated Other Comprehensive Income | (1.5B) | (1.8B) | (1.3B) | (1.3B) | (1.5B) | (1.6B) | |
Short Term Debt | 3.5B | 2.5B | 5.1B | 4.4B | 3.3B | 3.4B | |
Intangible Assets | 64.0B | 53.2B | 42.8B | 36.4B | 27.5B | 28.9B | |
Accounts Payable | 2.4B | 2.7B | 2.9B | 3.0B | 3.3B | 1.9B | |
Short Term Investments | 3.0B | 1.3B | 3.2B | 130M | 816M | 775.2M | |
Other Liab | 15.9B | 12.3B | 11.0B | 7.4B | 8.5B | 4.9B | |
Other Assets | 4.8B | 7.3B | 3.3B | 2.9B | 3.3B | 3.3B | |
Long Term Debt | 43.4B | 48.3B | 39.6B | 35.1B | 36.7B | 38.5B | |
Treasury Stock | (25.4B) | (26.2B) | (31.3B) | (38.6B) | (43.8B) | (41.6B) | |
Property Plant Equipment | 6.3B | 5.9B | 6.0B | 6.3B | 7.2B | 5.8B | |
Current Deferred Revenue | 4.5B | 3.6B | 3.7B | 1.3B | 4.2B | 4.4B | |
Net Tangible Assets | (34.9B) | (36.0B) | (28.2B) | (25.9B) | (23.4B) | (22.2B) | |
Noncontrolling Interest In Consolidated Entity | 96M | 100M | 60M | 57M | 55M | 74.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.34 | Earnings Share (3.10) | Revenue Per Share 22.212 | Quarterly Revenue Growth 0.047 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.